Smoking and lifespan: how many years does each cigarette cost?

Doll et al. (BMJ, 2004) followed 34,439 British male physicians for 50 years — one of the longest and most rigorous prospective cohort studies ever conducted. The headline finding: lifelong smokers died on average 10 years earlier than non-smokers. Jha et al. (NEJM, 2013) confirmed this in a modern US cohort of 215,000 adults, finding that smokers had three times the mortality rate of never-smokers in the 55–74 age group. The Global Burden of Disease study estimates that tobacco kills approximately 8 million people per year globally, making it the single largest cause of preventable death.

The dose-response relationship

The relationship between smoking and mortality is dose-dependent, but there is no safe threshold. Light smokers (1–9 cigarettes per day) have approximately 1.5–2× the all-cause mortality risk of never-smokers. Moderate smokers (10–19 per day) have 2–3× the risk. Heavy smokers (20+ per day) have 3–5× the risk. Crucially, occasional or 'social' smokers are not protected: even 1–4 cigarettes per day is associated with a significantly elevated risk of cardiovascular disease and lung cancer. The Nurses' Health Study found that women smoking 1–14 cigarettes per day had 5× the risk of fatal coronary heart disease compared to never-smokers.

What smoking does to your biology

Cigarette smoke contains over 7,000 chemicals, of which at least 69 are known carcinogens. The primary mechanisms of harm are: (1) Oxidative stress — cigarette smoke generates reactive oxygen species that damage DNA, proteins, and lipids throughout the body. (2) Inflammation — nicotine and combustion products activate NF-κB, driving systemic chronic inflammation. (3) Epigenetic aging — multiple studies using Horvath-style clocks have found that smoking accelerates biological age by 1–5 years depending on pack-year history, with some heavy smokers showing 10+ year acceleration. (4) Telomere shortening — smokers have measurably shorter telomeres than age-matched non-smokers, with each pack-year associated with approximately 0.5% shorter telomere length. (5) Mitochondrial dysfunction — cigarette smoke impairs mitochondrial electron transport chain function, reducing cellular energy production and increasing mitochondrial ROS generation.

Cancer risk: the full picture

Smoking is causally linked to at least 15 types of cancer. Lung cancer is the most well-known, with smokers having a 15–30× elevated risk compared to never-smokers. But the cancer burden extends far beyond the lungs: smoking causes cancers of the mouth, throat, oesophagus, stomach, pancreas, kidney, bladder, cervix, and a type of leukaemia. The International Agency for Research on Cancer (IARC) classifies tobacco smoke as a Group 1 carcinogen — the highest certainty category. Approximately 30% of all cancer deaths in high-income countries are attributable to smoking.

Cardiovascular and cerebrovascular damage

Smoking accelerates atherosclerosis through multiple mechanisms: endothelial dysfunction, increased LDL oxidation, platelet activation, and elevated fibrinogen. The Framingham Heart Study found that smoking doubled the risk of cardiovascular disease. Smokers have a 2–4× elevated risk of stroke. Carbon monoxide from cigarette smoke binds haemoglobin with 200× the affinity of oxygen, chronically reducing oxygen delivery to tissues. Even passive smoke exposure — living with a smoker — increases cardiovascular risk by approximately 25–30%.

Lifespan recovery after quitting: the timeline

The recovery from smoking is substantial and begins within hours of the last cigarette. Within 20 minutes, heart rate and blood pressure drop. Within 12 hours, carbon monoxide levels in the blood normalise. Within 2–12 weeks, circulation improves and lung function increases. Within 1 year, excess coronary heart disease risk drops by 50%. Within 5 years, stroke risk falls to that of a non-smoker. Within 10 years, lung cancer risk falls to approximately half that of a continuing smoker. Within 15 years, coronary heart disease risk approaches that of a never-smoker.

Doll et al. found that quitting at age 30 reduced excess mortality risk to near-never-smoker levels — recovering virtually all 10 years lost. Quitting at 40 recovered approximately 9 of the 10 years. Quitting at 50 recovered approximately 6 years. Quitting at 60 still recovered approximately 3 years. The message is unambiguous: it is never too late to quit, and the earlier the better.

The epigenetic recovery

A 2021 study in EBioMedicine found that smoking-associated DNA methylation changes begin to reverse within weeks of quitting. Some methylation sites return to never-smoker levels within 5 years of cessation. However, certain sites — particularly those associated with lung cancer risk — remain altered for decades after quitting, which explains why ex-smokers retain elevated lung cancer risk even 20 years after cessation. This epigenetic memory is one reason why quitting earlier in life produces greater biological benefit.

Cessation strategies: what actually works

Willpower alone has a 5–7% success rate at 12 months. Combining pharmacotherapy with behavioural support raises this to 25–35%. The most effective pharmacological interventions are: (1) Varenicline (Chantix/Champix) — a partial nicotinic receptor agonist that reduces cravings and the rewarding effects of smoking. Cochrane meta-analyses show it is the most effective single pharmacotherapy, with an odds ratio of approximately 2.5 for cessation at 12 months compared to placebo. (2) Nicotine replacement therapy (NRT) — patches, gum, lozenges, and inhalers all approximately double cessation rates compared to placebo. Combining long-acting (patch) with short-acting (gum/lozenge) NRT is more effective than either alone. (3) Bupropion — an antidepressant that also reduces nicotine cravings, approximately doubling cessation rates. Combining varenicline with NRT is more effective than either alone.